Stock listing
A2AC9U Stock Price, News, Filings & Events — Innoviva, Inc.
Selected listing: A2AC9U · LSX · EUR · DE
This page tracks Innoviva, Inc.'s A2AC9U:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2AC9U:LSX. A2AC9U:LSX is the stock-level entry point for investors researching Innoviva, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A2AC9U:LSX
- Asset type
- Stock
- Market cap
- $1.49B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LSX
- Currency
- EUR
Innoviva, Inc. A2AC9U:LSX stock context
This page tracks Innoviva, Inc.'s A2AC9U:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2AC9U:LSX. A2AC9U:LSX is the stock-level entry point for investors researching Innoviva, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Innoviva, Inc.
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
August 5, 2026
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
June 16, 2026
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
May 6, 2026
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmar...
March 10, 2026
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
February 25, 2026
Research Innoviva, Inc.
Innoviva, Inc. investor report
Review AI stock analysis and investor report context for A2AC9U:LSX.
Innoviva, Inc. company profile
View the public company page for Innoviva, Inc. on 6ix.
Innoviva, Inc. news
Read company news and market updates connected to Innoviva, Inc..
Innoviva, Inc. investor events
Find investor webinars, events, and replay context for Innoviva, Inc..
Alternate listings
INVA:NASDAQ
US · USD
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.
HVE:GETTEX
DE · EUR
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.
A2AC9U:LS
DE · EUR
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.
HVE:FWB
DE · EUR
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.
INVA:BOATS
US · USD
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.
HVE:TRADEGATE
DE · EUR
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.
HVE:MUN
DE · EUR
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.
HVE:BX
CH · CHF
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.
HVE:DUS
DE · EUR
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.
HVE:SWB
DE · EUR
Alternate listing for Innoviva, Inc.; the primary context on this page is A2AC9U:LSX.